Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022
Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens ...